The cost of employee turnover in a Clinical Research Organisation (CRO) is high, as it weakens the relationship with the project sponsor. Research shows that in 2012, the CRO industry in the United States experienced a 12.5% voluntary turnover, compared to an average national voluntary turnover rate of 1.5%. During the 2015 financial year, George Clinical […]
Read MoreIn a surprise move, the State Council in China has recently released a directive announcing its view on reforming the drug and medical device review and approval process in China. The State Council oversees the Chinese Food and Drug Administration (CFDA), and it is noteworthy that these changes were announced at a high level, reflecting […]
Read MoreGeorge Clinical in China recently celebrated its second anniversary as an independent entity in China. Although George Clinical has been conducting Phase 11 to Phase IV studies in China for over 8 years, previously it was incorporated into The George Institute in China – but now operates as a separate legal entity. The last two […]
Read MoreChina is a highly attractive clinical trial destination, and continues to see increased interest from CROs and drug development companies. China has a well-established tradition of developing medicines from basic research and the demands for modern pharmaceuticals is growing. Data gathered from clinicaltrials.gov indicated that in 2014, China had conducted 846 clinical trials, and an […]
Read MoreGeorge Clinical (GC) is at the heart of developing Asia Clinical Research Professionals. This summer, our Clinical and Regulatory Manager, East Asia volunteered as a trainer for Asia Training Consortium (ATC) in its Foundational Clinical Project Management training program in Hong Kong. ATC is a non-profit organisation aimed at providing a unified platform for industry […]
Read MoreThe Therapeutic Goods Administration (TGA) has released a new online form for the clinical trial notification (CTN) scheme. When a clinical trial is investigating the use of a product within Australia, which is not on the Australian Register of Therapeutic Goods (ARTG), or on the ARTG yet being used outside its marketing approval conditions, these […]
Read More
The George Institute was recently profiled in The Lancet; revered as one of the most prestigious, peer reviewed medical journals in the world. The Lancet Vol. 385 April 18, 2015 The feature article in The Lancet spoke of the Institute’s 16 year history from inception to the present time, where the George Institute is known […]
Read More
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise
Read More
Over the last three years, The George Institute’s Associate Professor Zhang Puhong has led a very important and significant study on Type 2 diabetes in China, the ORBIT (Observational Registry for Basal Insulin Treatment) study. Professor Ji Linong, the chief physician of the department of endocrinology in Peking University People’s hospital, was the principal investigator. […]
Read More
